HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vincenzo Di Marzo Selected Research

Guanosine 5'-O-(3-Thiotriphosphate)

6/2010The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
6/2009Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Vincenzo Di Marzo Research Topics

Disease

56Pain (Aches)
01/2022 - 03/2002
50Obesity
01/2022 - 07/2006
47Inflammation (Inflammations)
01/2022 - 01/2002
24Neoplasms (Cancer)
01/2022 - 01/2002
23Hyperalgesia
02/2021 - 08/2002
18Neuralgia (Stump Neuralgia)
02/2021 - 09/2004
18Multiple Sclerosis
01/2020 - 03/2002
13Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 05/2005
11Colitis
01/2021 - 03/2006
11Body Weight (Weight, Body)
02/2020 - 06/2002
10Neurodegenerative Diseases (Neurodegenerative Disease)
02/2019 - 01/2008
9Schizophrenia (Dementia Praecox)
10/2022 - 08/2003
9Insulin Resistance
01/2022 - 11/2009
8Overweight
09/2021 - 04/2008
8Alzheimer Disease (Alzheimer's Disease)
01/2020 - 09/2007
8Type 2 Diabetes Mellitus (MODY)
11/2019 - 08/2006
7Cognitive Dysfunction
10/2022 - 06/2009
7Epilepsy (Aura)
01/2021 - 08/2006
6Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 09/2003
6Huntington Disease (Huntington's Disease)
01/2020 - 03/2003
5Parkinson Disease (Parkinson's Disease)
11/2021 - 07/2005
5Seizures (Absence Seizure)
06/2020 - 10/2003
5Nervous System Diseases (Neurological Disorders)
01/2020 - 11/2007
5Neuroblastoma
01/2016 - 08/2008
5Weight Loss (Weight Reduction)
01/2014 - 08/2006
5Hyperglycemia
05/2013 - 08/2006
5Feeding and Eating Disorders (Eating Disorder)
01/2007 - 11/2003
4Mood Disorders (Mood Disorder)
01/2020 - 01/2010
4Hyperinsulinism (Hyperinsulinemia)
12/2019 - 08/2006
4Dyslipidemias (Dyslipidemia)
01/2019 - 01/2007
4Osteoporosis
10/2016 - 05/2011
4Albuminuria
01/2016 - 04/2010
4Diabetic Nephropathies (Diabetic Nephropathy)
01/2016 - 04/2010
4Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
05/2013 - 03/2006
4Glioma (Gliomas)
08/2012 - 02/2002
4Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
02/2006 - 01/2004
3Mental Disorders (Mental Disorder)
01/2021 - 11/2003
3Neurobehavioral Manifestations
01/2021 - 06/2009
3Gliosis
02/2020 - 09/2007

Drug/Important Bio-Agent (IBA)

137EndocannabinoidsIBA
10/2022 - 02/2002
58CannabinoidsIBA
01/2021 - 03/2002
33anandamide (arachidonylethanolamide)IBA
09/2020 - 03/2002
25Cannabinoid Receptors (Cannabinoid Receptor)IBA
04/2016 - 03/2002
21CannabidiolIBA
01/2021 - 09/2006
19CB1 Cannabinoid Receptor (CB1 Receptor)IBA
01/2020 - 08/2002
18LipidsIBA
01/2022 - 04/2003
17palmidrolIBA
01/2020 - 08/2002
14EnzymesIBA
01/2022 - 08/2002
14Analgesics (Analgesic Drugs)IBA
01/2018 - 03/2002
13Formaldehyde (Formol)FDA Link
02/2021 - 03/2002
12LigandsIBA
01/2021 - 05/2005
12glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA
01/2021 - 09/2003
12CB2 Cannabinoid ReceptorIBA
01/2019 - 08/2003
11Dronabinol (THC)FDA LinkGeneric
01/2020 - 05/2003
11fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA
01/2016 - 08/2002
10CarrageenanIBA
01/2018 - 09/2004
9LeptinIBA
12/2021 - 06/2005
9RimonabantIBA
11/2013 - 12/2002
8OrexinsIBA
05/2022 - 06/2013
8Proteins (Proteins, Gene)FDA Link
11/2021 - 09/2007
8arachidonoylserotoninIBA
01/2017 - 03/2006
7AmidesIBA
01/2021 - 08/2002
7Messenger RNA (mRNA)IBA
01/2021 - 08/2003
7Fatty Acids (Saturated Fatty Acids)IBA
01/2021 - 08/2002
7Dopamine (Intropin)FDA LinkGeneric
01/2021 - 07/2005
7Serotonin (5 Hydroxytryptamine)IBA
11/2019 - 09/2005
6Insulin (Novolin)FDA Link
01/2021 - 08/2007
6arvanilIBA
08/2012 - 03/2002
5AM 251 (AM251)IBA
10/2022 - 04/2010
5N-acylethanolaminesIBA
01/2022 - 01/2019
5AcidsIBA
01/2022 - 08/2007
52,4-dinitrofluorobenzene sulfonic acidIBA
01/2021 - 03/2006
5Biological ProductsIBA
01/2021 - 09/2005
5Glucose (Dextrose)FDA LinkGeneric
11/2020 - 01/2014
5Therapeutic UsesIBA
01/2020 - 08/2008
5Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2016 - 06/2013
5TRPV Cation ChannelsIBA
08/2012 - 03/2002
5CalciumIBA
05/2011 - 04/2003
4Pharmaceutical PreparationsIBA
01/2022 - 06/2013
4Antipsychotic Agents (Antipsychotics)IBA
11/2021 - 08/2003
4CytokinesIBA
02/2021 - 01/2014
4Oxaliplatin (Eloxatin)FDA LinkGeneric
02/2021 - 08/2013
4Ethanolamine (Colamine)IBA
01/2021 - 03/2005
4oleoylethanolamideIBA
01/2019 - 05/2004
4cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA
01/2013 - 09/2005
4Capsaicin (Zostrix)FDA Link
09/2012 - 04/2003
4N- (2- methyl- 3- hydroxyphenyl)- 5,8,11,14- eicosatetraenamideIBA
09/2005 - 12/2002
3Methylazoxymethanol AcetateIBA
10/2022 - 01/2019
3Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2017
3N-oleoylglycineIBA
01/2021 - 01/2020
3Fish OilsIBA
01/2021 - 08/2009
3Morphine (MS Contin)FDA LinkGeneric
01/2021 - 02/2020
3Naloxone (Narcan)FDA LinkGeneric
01/2021 - 02/2020
3DinitrobenzenesIBA
01/2021 - 11/2009
32-pentadecyl-2-oxazolineIBA
01/2021 - 01/2017
3Glutamic Acid (Glutamate)FDA Link
01/2021 - 07/2007
3Sulfonic AcidsIBA
01/2021 - 03/2006
3Glycerol (Glycerine)FDA LinkGeneric
12/2020 - 07/2005
3LipopolysaccharidesIBA
02/2020 - 12/2004

Therapy/Procedure

19Therapeutics
01/2021 - 06/2002